SNY — Sanofi catalysts
Next verified catalyst
2026-06-29 — A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-06-29 in 7d
ESTIMATED |
READOUT
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Su
Phase 3 · Dermatitis Atopic |
SNY Sanofi | Amlitelimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-06-30 in 8d
ESTIMATED |
READOUT
Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV
Phase 4 · RSV Immunization |
SNY Sanofi | Nirsevimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-07-10 in 18d
ESTIMATED |
READOUT
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus
Phase 2 · Systemic Lupus Erythematosus |
SNY Sanofi | SAR441344 IV, SAR441344 SC |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08-05 in 1mo
ESTIMATED |
READOUT
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adu
Phase 2 · Coeliac Disease, Celiac Disease |
SNY Sanofi | Amlitelimab, SIGE, Gluten-free product ( |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08-08 in 2mo
ESTIMATED |
READOUT
A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric P
Phase 3 · Yellow Fever Immunization |
SNY Sanofi | Yellow fever vaccine (live), Yellow feve |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08-25 in 2mo
ESTIMATED |
READOUT
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Partici
Phase 2 · Graves' Disease |
SNY Sanofi | Rilzabrutinib dose 1, Rilzabrutinib dose |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08-27 in 2mo
ESTIMATED |
READOUT
Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Phase 4 · Diabetes Mellitus, Type 1 |
SNY Sanofi | teplizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-09-29 in 3mo
ESTIMATED |
READOUT
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Pa
Phase 2 · Asthma |
SNY Sanofi | Amlitelimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-10-14 in 4mo
ESTIMATED |
READOUT
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (
Phase 3 · Chronic Rhinosinusitis With Nasal Polyps |
SNY Sanofi | Itepekimab (SAR440340), Mometasone furoa |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-11-06 in 5mo
ESTIMATED |
READOUT
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (
Phase 3 · Chronic Rhinosinusitis With Nasal Polyps |
SNY Sanofi | Itepekimab (SAR440340), Mometasone furoa |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|